Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
504 hedge funds and large institutions have $29B invested in Alexion Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 78 funds opening new positions, 179 increasing their positions, 203 reducing their positions, and 29 closing their positions.
169% more first-time investments, than exits
New positions opened: 78 | Existing positions closed: 29
15% more capital invested
Capital invested by funds: $25.3B → $29B (+$3.69B)
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
9% more funds holding
Funds holding: 463 → 504 (+41)
3% less call options, than puts
Call options by funds: $194M | Put options by funds: $200M
12% less repeat investments, than reductions
Existing positions increased: 179 | Existing positions reduced: 203
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$191M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$177M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$156M |
| 4 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$116M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$97.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
-$334M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$265M |
| 3 |
TCIM
TIAA CREF Investment Management
New York
|
-$166M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
-$165M |
| 5 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$155M |
ALXN Hedge Fund Activity: Q1 2014 in Review
504 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q1 2014, worth a combined $29B — up 15% from $25.3B a quarter earlier.
Buyers outnumbered sellers: 78 funds opened new ALXN positions and 29 closed out — a net gain of 49 holders — while 179 added to existing stakes and 203 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $191M. The largest seller was Sands Capital Management, cutting an estimated $334M.
- 504 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q1 2014, up from 463 in Q4 2013.
- Funds reported $29B of Alexion Pharmaceuticals stock for Q1 2014, up 15% quarter-over-quarter.
- 78 funds opened new Alexion Pharmaceuticals positions in Q1 2014 and 29 closed out, a net change of +49 holders.
- The largest Alexion Pharmaceuticals buyer in Q1 2014 was JP Morgan Chase, an estimated $191M added.
- The largest Alexion Pharmaceuticals seller in Q1 2014 was Sands Capital Management, an estimated $334M sold.
Based on aggregated 13F filings for Q1 2014.